Improving Delivery Efficiency & Unlocking New Indications Through Antibody-Fragment Conjugates
- Antikor’s platform for recombinant antibody fragments optimized for developability and payload bioconjugation
- Process for Antibody Fragment Drug Conjugate (FDC) discovery, tailoring the linker-payload
- Update on ANT-045, our lead FDC program for cMET-expressing solid tumours
- An insight into Antikor’s follow up projects